Novartis AG/ US66987V1098 /
7/7/2022 6:11:18 PM | Chg. +0.59 | Volume | Bid6:11:37 PM | Ask6:11:37 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
84.31USD | +0.70% | 15,078 Turnover: 1.27 mill. |
77.43Bid Size: 100 | 84.29Ask Size: 200 | 195.26 bill.USD | - | - |
GlobeNewswire
3/15
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
GlobeNewswire
3/8
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
GlobeNewswire
1/4
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to includ...
GlobeNewswire
12/16/2021
Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline
GlobeNewswire
12/2/2021
Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 po...
GlobeNewswire
6/16/2021
Axtria Leads Discussion on Pharma’s Advanced Uses of Data Analytics and Artificial Intelligence With...
GlobeNewswire
5/17/2021
US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
GlobeNewswire
4/7/2021
Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
GlobeNewswire
4/7/2021
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
GlobeNewswire
2/16/2021
Novartis Entresto® granted expanded indication in chronic heart failure by FDA